RAPT Therapeutics
Biotechnology ResearchView the employees at
RAPT Therapeutics-
Scott Auerbach Graduate Student at Bilkent University
-
Ankara, Turkey
-
Top 10%
Sherry Jiao Scientist-
San Francisco Bay Area
-
Rising Star
Haley Griffiths Research Associate II, Inflammation & Discovery Biology-
Rising Star
Paul Kassner Senior Vice President of Quantitative and Computational Biology at RAPT Therapeutics-
San Mateo
-
Top 10%
Overview
RAPT Therapeutics is a clinical stage immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The company is also pursuing a range of targets that are in the discovery stage of development.
-